Financial Data and Key Metrics Changes - The company reported a record revenue of $40.8 million for FY 2025, representing a 10% increase compared to the previous period [9][21] - Annual Recurring Revenue (ARR) reached $28.5 million as of June 30, 2025, marking a 31% increase year-over-year [10][23] - The company achieved a record underlying EBITDA of $5.1 million, an improvement of $8.5 million from the previous year [12][24] - Positive operating cash flow of $5.8 million was generated during the year, a turnaround of $12.9 million compared to the prior year [13][30] Business Line Data and Key Metrics Changes - The company signed new Total Contract Value (TCV) of $73.8 million, more than doubling the previous year's figures [12][31] - The UK market contributed 63% of total revenue in FY 2025, surpassing the ANZ region for the first time [26] - The modular architecture of the Mya Precision platform allows for incremental sales without extensive implementation efforts, enhancing customer flexibility [5][39] Market Data and Key Metrics Changes - The company operates in three main geographies: Australia, New Zealand, and the United Kingdom, with plans for potential expansion into Canada, Saudi Arabia, and the UAE [6][42] - The healthcare sector is increasingly focused on patient flow solutions, which are critical for hospital administrators [34] Company Strategy and Development Direction - The company aims to scale existing core products and markets, particularly in EPR flow and virtual care opportunities [41] - There is a focus on leveraging Mya Precision capabilities in other health verticals such as aged care and community care [41] - The company is exploring strategic M&A opportunities to enhance growth [42] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future growth trajectory, citing a strong pipeline and increasing referenceability in the market [41][43] - The company anticipates continued growth in contracted revenue and positive EBITDA for FY 2026 [40][41] Other Important Information - The company appointed new directors with extensive healthcare experience to strengthen its leadership team [16][17] - The modular sales strategy has proven successful, allowing for flexibility in meeting customer needs over time [39] Q&A Session Summary Question: Can you provide more detail on the structure of capital license purchases? - The capital license includes an upfront fee for a specified period, with ongoing support and maintenance fees that are annually recurring [44][46] Question: What does the pipeline look like? - The pipeline continues to build due to customer deployments and market opportunities, but specific contract timelines cannot be predicted [47][48] Question: Can you provide an update on the relationship with Dartford and Gravesham NHS Trust? - The trust is working through funding allocation processes and has not yet gone to market for an EPR [50] Question: What are the expectations around staffing and expenses moving forward? - Staffing levels are expected to remain stable, with investments in sales and marketing capabilities [51][52] Question: How does the company plan to ensure future M&A activities deliver value to shareholders? - The company evaluates M&A opportunities based on valuation, expected returns, and support for future growth [53][55] Question: Should we expect gross margin expansion in FY 2026? - Gross margin is expected to improve as ARR increases, barring any significant changes in product mix [56] Question: How big is the opportunity in the UK? - The UK market presents significant opportunities for digitization and modular solutions, although exact dollar amounts are uncertain [58][59] Question: What feedback was received from the trial software provided to an emergency hospital in Manchester? - The trial was a successful entry point into the UK market, and similar proof-of-concept trials may be considered for new markets [60][62]